U.S. Department of Veterans Affairs

08/13/2026 | Press release | Distributed by Public on 08/13/2026 13:30

VA secures $10B+ in pharmaceutical price reductions so far in FY 2026

WASHINGTON - The Department of Veterans Affairs today announced it has secured a record-high $10.44 billion in pharmaceutical price reductions so far in fiscal year 2026 - nearly double the value achieved in the last year of the Biden Administration.

During the second Trump Administration, VA launched a major effort to secure lower prices on the pharmaceuticals the department uses most frequently to treat Veterans, and this effort has yielded the highest level of price reductions ever recorded. Lower prices on pharmaceuticals enable VA to treat more Veterans and focus on emerging therapies that can be more expensive at the beginning of their product life cycle.

In FY 2024, VA achieved $5.23 billion in price reductions through these negotiations. But under President Trump, VA achieved $7.99 billion in price reductions in FY 2025 and is benefitting from $10.44 billion in price reductions so far in FY 2026.

"Under President Trump, VA is racking up huge wins for Veterans and taxpayers by demanding a better deal from pharmaceutical companies," said VA Secretary Doug Collins. "Our team already provides world-class care for Veterans, and through smart, tough negotiations with drugmakers, we will continue to deliver more care and better care than ever before."

Making the most effective use of congressional funding is just one of several steps VA is taking to serve Veterans better. For example, VA has:

U.S. Department of Veterans Affairs published this content on August 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 13, 2026 at 19:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]